Cannabidiol potentiates phenobarbital-induced cell death in the developing brain

Area of Science:

• Neuroscience
• Pharmacology
• Pediatric Neurology

Background:

• Epilepsy affects 1% of the global population, with higher prevalence in children.
• Phenobarbital (PB) is a common antiseizure medication (ASM) for pediatric epilepsy but is effective in only two-thirds of cases and can cause neurotoxicity.
• Cannabidiol (CBD) is a promising alternative ASM with fewer side effects and neuroprotective potential, but its safety in developing brains is unclear.

Purpose of the Study:

• To evaluate the safety profile of cannabidiol (CBD) in immature rodent brains.
• To assess potential neurodegenerative effects of CBD using Fluoro-Jade C staining.
• To investigate the combined effects of CBD and phenobarbital (PB) on neuronal cell death in developing brains.

Main Methods:

• Immature Wistar rats (postnatal day 7) were administered CBD at doses of 2, 20, and 200 mg/kg.
• Neuronal cell death was assessed 24 hours later using Fluoro-Jade C histochemical staining.
• A combination group received CBD (30 mg/kg) with PB (75 mg/kg) to evaluate synergistic neurotoxic effects.

Main Results:

• CBD administration alone did not increase neuronal cell death compared to control groups across all tested doses.
• Combining CBD (30 mg/kg) with PB (75 mg/kg) significantly increased neuronal death.
• The PB+CBD combination group exhibited over double the neurodegeneration observed with PB alone.

Conclusions:

• CBD appears safe as a monotherapy in immature rodent brains at the tested doses.
• CBD may exacerbate PB-induced neurotoxicity when co-administered, potentially negating its neuroprotective benefits.
• Clinical caution is warranted when combining CBD with PB for pediatric epilepsy treatment due to potential increased neurotoxicity.